PUBLICATIONS

• Hsu M, Jung OS, Kwan LT, Jegede O, Martin B, Malhotra A, Suzuki J. Access challenges to opioid use disorder treatment among individuals experiencing homelessness: Voices from the streets. J Subst Use Addict Treat. 2023 Nov 18; 157:209216. PMID: 37981243.
• Rodriguez CP, Suzuki J. Case series: Voluntary discontinuation of sublingual buprenorphine treatment for opioid use disorder using extended-release buprenorphine. Am J Addict. 2023 05; 32(3):314-317. PMID: 36941795. PMC10121911.
• Hathaway DB, Bhat JA, Twark C, Rodriguez C, Suzuki J. Patients’ experiences with continuation or discontinuation of buprenorphine before painful procedures: A brief report. Am J Addict. 2023 07; 32(4):410-414. PMID: 36850041.
• Ahmed S, Faruqui Z, Poddar K, Bhivandkar S, Suzuki J. Low-dose buprenorphine initiation in the era of fentanyl and fentanyl analogs: A case series of outpatient inductions. J Opioid Manag. 2023 Sep-Oct; 19(5):455-460. PMID: 37968979.
• Funk MC, Nash S, Smith A, Barth K, Suzuki J, Rustad JK, Buonocore S, Khandai AC, Smith MA, Jin S, Drexler K, Renner JA. Treatment of Opioid Use Disorder in the General Hospital. Am J Psychiatry. 2023 Aug 01; 180(8):594-596. PMID: 37525604. PMC10998288.
• Ahmed S, Bhivandkar S, Lonergan BB, Suzuki J. Microinduction of Buprenorphine/Naloxone: A Review of the Literature. Am J Addict. 2021 07; 30(4):305-315. PMID: 33378137.

• Suzuki J, Martin B, Loguidice F, Smelson D, Liebschutz JM, Schnipper JL, Weiss RD. A Peer Recovery Coach Intervention for Hospitalized Patients with Opioid Use Disorder: A Pilot Randomized Controlled Trial. J Addict Med. 2023 Sep-Oct 01; 17(5):604-607. PMID: 37788617. PMC10544697.
• Suzuki J, Loguidice F, Prostko S, Szpak V, Sharma S, Vercollone L, Garner C, Ahern D. Digitally Assisted Peer Recovery Coach to Facilitate Linkage to Outpatient Treatment Following Inpatient Alcohol Withdrawal Treatment: Proof-of-Concept Pilot Study. JMIR Form Res. 2023 Jul 05; 7:e43304. PMID: 37405844. PMC10357372.
• Suzuki J, Loguidice F, Martin B. Attitudes Regarding Medications for Opioid Use Disorder Among Peer Recovery Coaches. J Addict Med. 2023 Jan-Feb 01; 17(1):101-103. PMID: 35914085. PMC9889565.
• Suzuki J,  Szpak V, Sager Z, Kim A: Survey of Massachusetts peer recovery coaches’ attitudes toward the use of psychedelics to treat substance use disorders. Addictive Science and Clinical Practice, 19(1):86, 2024 PMID 39587692 PMC 11587772

• Suzuki J, Martin B, Prostko S, Chai PR, Weiss RD. Cannabidiol Effect on Cue-Induced Craving for Individuals with Opioid Use Disorder Treated with Buprenorphine: A Small Proof-of-Concept Open-Label Study. Integr Med Rep. 2022 Aug 01; 1(1):157-163. PMID: 36105269.  PMC9462449.
• Suzuki J, Prostko S, Szpak V, Chai PR, Spagnolo PA, Tenenbaum RE, Ahmed S, Weiss RD. Impact of cannabidiol on reward- and stress-related neurocognitive processes among individuals with opioid use disorder: A pilot, double-blind, placebo-controlled, randomized cross-over trial. Front Psychiatry. 2023; 14:1155984. PMID: 37065899. PMC10098189.
• Suzuki J, Weiss RD. Cannabinoids for the Treatment of Opioid Use Disorder: Where is the Evidence? J Addict Med. 2021 04 01; 15(2):91-92. PMID: 32909980. PMC7986228.

• Suzuki J, Johnson JA, Montgomery MW, Hayden MC, Price CN, Solomon DA, Liebschutz JM, Schnipper JL, Weiss RD. Long-term Outcomes of Injection Drug-related Infective Endocarditis Among People Who Inject Drugs. J Addict Med. 2020 Jul/Aug; 14(4):282-286. PMID: 31634202.
• Suzuki J, Robinson D, Mosquera M, Solomon DA, Montgomery MW, Price CD, Johnson JA, Martin B, Liebschutz JW, Schnipper JL, Weiss RD. Impact of Medications for Opioid Use Disorder on Discharge Against Medical Advice Among People Who Inject Drugs Hospitalized for Infective Endocarditis. Am J Addict. 2020 03; 29(2):155-159. PMID: 31930608. PMC7035155.
• Price CN, Solomon DA, Johnson JA, Montgomery MW, Martin B, Suzuki J. Feasibility and Safety of Outpatient Parenteral Antimicrobial Therapy in Conjunction With Addiction Treatment for People Who Inject Drugs. J Infect Dis. 2020 09 02; 222(Suppl 5):S494-S498. PMID: 32877541. PMC7566637.
• Kim JH, Fine DR, Li L, Kimmel SD, Ngo LH, Suzuki J, Price CN, Ronan MV, Herzig SJ. Disparities in United States hospitalizations for serious infections in patients with and without opioid use disorder: A nationwide observational study. PLoS Med. 2020 08; 17(8):e1003247. PMID: 32764761.
• Messinger JC, Suzuki J. Recognizing and Reducing the Impact of Trauma of Hospitalization: Considerations for Persons Who Use Drugs. J Addict Med. 2022 Jan-Feb 01; 16(1):7-9. PMID: 33758115. PMC8449792
• Szpak V, Prostko S, Weiss RD, Suzuki J. Developing a remotely delivered intensive outpatient program adapted for hospitalized patients with opioid use disorder: A qualitative study. Addict Behav Rep. 2024 Jun; 19:100546. PMID: 38680207. PMC11046241.
  Wurcel AG, Suzuki J, Schranz AJ, Eaton EF, Cortes-Penfield N, Baddour LM. Strategies to Improve Patient-Centered Care for Drug Use-Associated Infective Endocarditis: JACC Focus Seminar 2/4. J Am Coll Cardiol. 2024 Apr 09; 83(14):1338-1347. PMID: 38569764.
• Zambrano S, Paras ML, Suzuki J, Pearson JC, Dionne B, Schrager H, Mallada J, Szpak V, Fairbank-Haynes K, Kalter M, Prostko S, Solomon DA . Real-World Dalbavancin Use for Serious Gram-Positive Infections: Comparing Outcomes Between People Who Use and Do Not Use Drugs. Open Forum Infect Dis. 2024 Apr; 11(4):ofae186. PMID: 38651139. PMC11034951.
• Szpak, V., Velez, A., Rosenblum, N., Prostko, S., Maurer, R., Weiss, R. D., & Suzuki, J. (In preparation) Pilot testing a novel remotely delivered intensive outpatient program for hospitalized patients with opioid use disorder: A brief report

• Goldfine CE, Tom JJ, Im DD, Yudkoff B, Anand A, Taylor JJ, Chai PR, Suzuki J. The therapeutic use and efficacy of ketamine in alcohol use disorder and alcohol withdrawal syndrome: a scoping review. Front Psychiatry. 2023; 14:1141836. PMID: 37181899. PMC10172666.
• Shay JES, Vannier A, Tsai S, Mahle R, Diaz PM, Przybyszewski E, Challa PK, Patel SJ, Suzuki J, Schaefer E, Goodman RP, Luther J. Moderate-high intensity exercise associates with reduced incident alcohol-associated liver disease in high-risk patients. Alcohol Alcohol. 2023 Sep 09; 58(5):472-477. PMID: 37565935. PMC10493517.
• Winder GS, Clifton EG, Denysenko L, DiChiara AM, Hathaway D, Perumalswami PV, Shenoy A, Suzuki J, Tareen K, Mellinger JL, Fernandez AC. “But I didn’t drink!”: What to do with discordant phosphatidylethanol results. Liver Transpl. 2024 Feb 01; 30(2):213-222. PMID: 37486958.
• Butterfield M, Thorne-Humphrey L, Suzuki J, Herschenhous N. Evaluation of a Novel Protocol for Assessment and Treatment of Alcohol Withdrawal Syndrome in Psychiatric Inpatients. Am J Addict. 2020 11; 29(6):500-507. PMID: 32490573.
• Felhofer A, Crowe T, AhnAllen CG, Mistler LA, Suzuki J. Assessment and Treatment of a Deaf Patient with Alcohol Use Disorder-Limitations and Special Considerations. Harv Rev Psychiatry. 2022 May-Jun 01; 30(3):198-206. PMID: 35452427.

•  Barnett BS, Chai PR, Suzuki J. Scaling Up Point-of-Care Fentanyl Testing – A Step Forward. N Engl J Med. 2023 Nov 02; 389(18):1643-1645. PMID: 37902291. PMC10872956.
• Edinoff AN, Hathaway DB, Martinez Garza D, Rosen JH, Suzuki J. The possible clinical utility of the alcohol biomarker phosphatidylethanol for managing suspected alcohol withdrawal in hospitalized patients: A case report. Am J Addict. 2024 May;33(3):351-353. PMID: 38319035. PMC11032224.

Shen MR, Owusu-Boaitey K, Holsen LM Suzuki J. The Efficacy of GLP-1 Agonists in Treating Substance Use Disorder in Patients: A Scoping Review. J Addict Med. 2024 Sep-Oct;18(5):488-498. PMID: 39092831.